ArticleJournal of clinical and experimental hepatology2014
Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study.
Article in Journal of clinical and experimental hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?World journal of gastroenterology · 2020Pooled it
- Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.World journal of gastroenterology · 2017Pooled it
- Autoimmune hepatitis: Towards a personalized treatment.World journal of hepatology · 2024Review
- Article
- Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis.Journal of translational autoimmunity · 2022Article
- The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.Hepatology international · 2021Article
- Mycophenolate mofetil-induced liver injury in a patient with aquaporin-4 antibody positive transverse myelitis.BMJ case reports · 2020Article
- The use of immunosuppression in autoimmune hepatitis: A current literature review.Clinical and molecular hepatology · 2017Review
- Refractory Autoimmune Hepatitis: Beyond Standard Therapy.Digestive diseases and sciences · 2016Article
- Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.Clinical and molecular hepatology · 2016Article
- Management of Difficult Cases of Autoimmune Hepatitis.Current gastroenterology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEighty percent (80%) of patients with Autoimmune hepatitis (AIH) respond to a combination of prednisolone and Azathioprine (AZA). Choice of treatment is limited for those who do not respond to this standard therapy. We evaluated the role of Mycophenolate mofetil (MMF) as a second line therapy in AIH.
methodA retrospective observational study was carried out on all patients who received MMF for AIH.
resultsTwenty out of 117 patients with AIH received MMF due to AZA intolerance (18 patients) or refractory disease (2 patients). Median age of the study patients was 56 (18-79) years, Male, n = 3 (15%) and Female, n = 18 (85%). After a median follow-up period of 47 (5-83) months, 14 (73.6%) patients were still on MMF with biochemical remission, including 4 out of 5 patients with cirrhosis. One patient was lost to follow-up. Three patients were intolerant of MMF due to adverse events, and two had disease refractory to MMF. Both these patients with refractory disease to MMF were initially unresponsive to AZA therapy.
conclusionMMF is a safe second line agent in patients with autoimmune hepatitis including those with cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.